Let\u2019s hear it for retail investors, who don\u2019t get enough credit for taking care of business. <\/p>\n
Citing Vanda Research, the Wall Street Journal reports that the average individual-investor stock portfolio is up 150% since the start of 2014, versus around 140% for the S&P 500\u2019s
\n SPX
\n during the same period. <\/p>\n
All that is largely thanks to love for tech biggies like Apple and Tesla, as savvy investors picked up on their importance. And who wouldn\u2019t want to hop on the next big theme and be sitting on big gains in a decade or two.<\/p>\n
That brings us to our call of the day<\/strong>, from JPMorgan, which is flagging a \u201c$100 billion plus opportunity\u201d from emerging weight-loss drugs, or GLP-1s \u2014 glucagon-like peptide-1 gut hormones that can help control blood sugar levels and lower appetites. <\/p>\n \u201cWe forecast U.S. sales for the GLP-1 category to exceed $100 billion in annual sales over time, split roughly 50\/50 in diabetes and obesity. Our global market estimate is [more than] $140 billion by 2032,\u201d said a team led by analyst Nicholas Rosato, whose estimates crush the $77 billion in sales by 2030 predicted by Morgan Stanley this summer.<\/p>\n His team is bullish on U.S. and Europe picks Eli Lilly Laying out other beneficiaries, they tamp down worries over medtech device makers \u2014 they are bullish views on Insulet In life sciences, they like Thermo Fisher JPMorgan analysts then address the hot-button topic \u2014 how those drugs will cut into the American love for snack foods and drinks. <\/p>\n Also read: <\/strong>The dark side of the weight-loss-drug craze: eating disorders, medication shortages, dangerous knockoffs<\/p>\n Walmart Echoing this, JP Morgan analysts say the impact is \u201creal and potentially not small,\u201d and share a survey showing GLP-1 users prefer meat, produce and dairy to snacks, sugary drinks and high carb items. Some caveats here, just under 500 people were surveyed and they say it\u2019s hard to tell if those category shifts will persist, they say:<\/p>\n <\/p>\n To this effect, Rosato and the team are bullish on protein drink maker BellRing What else? Within U.S. food delivery they are prefer the more global player Uber Read: <\/strong>Equity strategist who called stock rally in first half says S&P 500 won\u2019t resume climb until spring 2024<\/p>\n <\/p>\n Stock futures YM00, NQ00, BX:TMUBMUSD02Y Earnings are rolling out from big names on Tuesday \u2014 GE Alphabet Read:<\/strong> Big-tech results will decide \u2018where we go from here\u2019 amid investor caution. They would fall if it weren\u2019t for this one company<\/p>\n The S&P flash U.S. manufacturing and services purchasing managers indexes are due at 9:45 a.m.<\/p>\n Global demand for fossil fuels will peak before the end of the decade, as geopolitics hasten the move to renewable energy, says the International Energy Agency. <\/p>\n Israel-Hamas war sees investors shun most traditional havens, except for these two.<\/p>\n Microsoft and NBA offer menopause benefits to keep women working.<\/p>\n Coming of age in Ukraine.<\/p>\n These were the top-searched tickers on MarketWatch as of 6 a.m.:<\/p>\n Skeletal, Taylor Swift-inspired Halloween lawn d\u00e9cor goes viral.<\/p>\n That 40 million year-old moon.<\/p>\n \u201cSiren battles\u201d blaring C\u00e9line Dion songs plague this New Zealand town.<\/p>\n
\n LLY,
\n
\n and Novo Nordisk
\n NVO,
\n
\n NOVO.B,
\n
\n and they see plenty of upside earnings surprises ahead for that pair. Note, the WSJ points out that Novo Nordisk, Europe\u2019s most valuable company, is vulnerable to selling in Europe at times as Danish fund managers can\u2019t hold more than 10% of the drugmaker.<\/p>\n
\n PODD,
\n
\n Dexcom
\n DXCM,
\n
\n and Inspire Medical
\n INSP,
\n
\n and Gerresheimer
\n GXI,
\n
\n TMO,
\n
\n Catalent
\n CTLT,
\n
\n and Avantor
\n AVTR,
\n
\n which makes process ingredients used in those diabetes\/weight loss drugs, and see incremental gains seen for Danaher
\n DHR,
\n
\n Repligen
\n RGEN,
\n
\n and Agilent
\n A,
\n
\n WMT,
\n
\n CEO John Furner sent shares of Coca-Cola
\n KO,
\n
\n and PepsiCo
\n PEP,
\n
\n tumbling a few weeks ago after he blamed GLP-drugs for lower spending on groceries and high-calorie snacks. (Coke lifted guidance as it reported forecast-beating results on Tuesday and shares are up) Morgan Stanley has been among Wall Street banks flagging this likely fallout. <\/p>\n
\n BRBR,
\n
\n and natural and organic grocery chain Sprouts Farmers Market
\n SFM,
\n
\n (neutral rated). They are also bullish on Coca-Cola, which they see as \u201crelatively more insulated\u201d from GLP-1 fallout as around 80% of its volumes are international and 19 out of its 20 top drinks offer sugar free alternatives. They also like Keurig Dr Pepper
\n KDP,
\n
\n as it\u2019s less exposed to sugary drinks. <\/p>\n
\n UBER,
\n
\n to DoorDash
\n DASH,
\n
\n and Instacart
\n CART,
\n
\n for its potential from secular growth of online grocery delivery. <\/p>\nThe markets<\/h2>\n
\n ES00,
\n
\n
\n
\n are higher as bond yields
\n BX:TMUBMUSD10Y<\/p>\n
\n steady, following Monday\u2019s dramatic 5% run for the 10-year note. Oil prices
\n CL.1,
\n
\n are flat, and bitcoin
\n BTCUSD,
\n
\n is climbing after reaching a nearly 18-month high on Monday over optimism that an ETF based on the crypto will soon be approved in the U.S.<\/p>\nThe buzz<\/h2>\n
\n GE,
\n
\n lifted guidance and the stock is climbing, 3M
\n MMM,
\n
\n is up on a higher outlook and profit beat and General Motors
\n GM,
\n
\n reported blowout earnings and shares are up. Xerox
\n XRX,
\n
\n is up after swinging to a profit. <\/p>\n
\n GOOGL,
\n
\n (see preview), Microsoft
\n MSFT,
\n
\n (see preview), Visa
\n V,
\n
\n and Texas Instruments
\n TXN,
\n
\n are due after the market close.<\/p>\nBest of the web<\/h2>\n
The tickers<\/h2>\n
\n
\n \n Ticker<\/p>\n<\/td>\n \n Security name<\/p>\n<\/td>\n<\/tr>\n \n \n TSLA,
\n \n Tesla<\/p>\n<\/td>\n<\/tr>\n \n \n NVDA,
\n \n Nvidia<\/p>\n<\/td>\n<\/tr>\n \n \n AMC,
\n \n AMC Entertainment<\/p>\n<\/td>\n<\/tr>\n \n \n AAPL,
\n \n Apple<\/p>\n<\/td>\n<\/tr>\n \n \n GME,
\n \n GameStop<\/p>\n<\/td>\n<\/tr>\n \n \n MARA,
\n \n Marathon Digital<\/p>\n<\/td>\n<\/tr>\n \n \n SPOT,
\n \n Spotify Technology<\/p>\n<\/td>\n<\/tr>\n \n \n PLTR,
\n \n Palantir Technologies<\/p>\n<\/td>\n<\/tr>\n \n \n MSFT,
\n \n Microsoft<\/p>\n<\/td>\n<\/tr>\n \n \n NIO,
\n \n NIO<\/p>\n<\/td>\n<\/tr>\n<\/table>\n Random reads<\/h2>\n